S-1 · primary offering
Issued 2024
Proposed maximum
Shares registered
- Filed
- Effective
Sector: Pharmaceutical PreparationsIndustry: Drug Manufacturers - Specialty & GenericCountry: CNExchange: Nasdaq
DilutionScan read 20 of Zhengye Biotechnology Holding Ltd's SEC filings and found 1 S-1 registration on file for ZYBT. The latest dilution event on file is a registration statement on Jan 9, 2024. Analysis updated Oct 12, 2026.
ZYBT
Shrinking revenue, Nasdaq bid-price scare
Zhengye is a tiny Chinese veterinary vaccine maker whose business shrank sharply: FY 2025 revenue fell 37.6% to $17.4M, and gross margin dropped to 20.5% from 49% the prior year.
Raise routes on file: no active ATM, effective shelf, S-1 or equity line in the filings read · latest dilution event 1029 days ago
The dominant contractual driver and its mechanism, then each further driver ranked.
Jan 9, 2024 · Registration
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Shares outstanding, potential dilution and cash over time
Issued 2024
Proposed maximum
Shares registered
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
DilutionScan ProEvery instrument in full · $59/mo
Covered companies in Drug Manufacturers - Specialty & Generic. All tickers A to Z